01 June 2009
By:Priyabrata Pattnaik, Tathagata Ray
The importance of liposomes as an effective drug delivery system is well accepted in the pharmaceutical industry, but their handling remains a challenge.
 |
01 May 2009
By:Ngoc Do, Jason Hansell, Thomas P. Farrell
Based on formulation simplicity and blinding capability, hard gelatin capsules are preferrable compared with other oral solid dosage forms, including tablets, in the early clinical phases of drug development.
|
01 February 2009
By:Maj-Britt Babbel, Bodo Fritzsching
During the past years, there has been increasing demand for fast dissolving disintegrating tablets (FDDTs), such as orally disintegrating tablets (ODTs) and sublinguals.
|
01 January 2009
By:Maureen Mistry
A new excipient for orally disintegrating tablets not only imparts superior tablet characteristics, but has the added advantage of allowing users to maintain full control over their formulations, manufacturing processes and intellectual property.
|
01 January 2009
By:Gavin P. Andrews, David S. Jones, Osama Abu Diak, Daniel N. Margetson, Mark S. McAllister
Hot-melt extrusion offers many advantages compared with conventional solid dosage form manufacturing, and has consequently received considerable attention from both the pharmaceutical industry and academia as a novel drug delivery technology. The possibility of forming solid dispersions with improved bioavailability renders hot-melt extrusion an excellent alternative to other conventionally employed techniques.
|
01 December 2008
By:Fridrun Podczeck
Microcrystalline cellulose is the main excipient used in the industrial manufacture of pellets by extrusion/spheronization, but pellets containing this spheronizing aid do not readily disintegrate and are expensive.
|
01 December 2008
By:Marina Levina, Ali R. Rajabi-Siahboomi
Research shows that both drug prescription and alcohol consumption increase within the elderly population. It is, therefore, necessary to fully understand the impact of alcohol consumption on solid oral dosage forms, especially extended release formulations.
|
| 
